For the p53 Special Issue
1098-1004/asset/HUMU_left.gif?v=1&s=4065e12063da1c0efe3c1a74d4f13c3cd92fba18)
1098-1004/asset/HUMU_right.gif?v=1&s=58026811b6aa5bee5a3d0e0563a705f8b681f34d)
p53 Review Article
You have free access to this content
Disrupting TP53 in mouse models of human cancers†
Article first published online: 24 FEB 2003
DOI: 10.1002/humu.10186
Copyright © 2003 Wiley-Liss, Inc.
Issue
1098-1004/asset/cover.gif?v=1&s=b02ab57a64d28403f477b09d50f72a4d63f4c8eb "Human Mutation")
Human Mutation
Special Issue: Focus on p53 and Cancer
Volume 21, Issue 3, pages 321–326, March 2003
Additional Information
How to Cite
Parant, J. M. and Lozano, G. (2003), Disrupting TP53 in mouse models of human cancers. Hum. Mutat., 21: 321–326. doi: 10.1002/humu.10186
- †
Publication History
- Issue published online: 24 FEB 2003
- Article first published online: 24 FEB 2003
REFERENCES
- , . 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268:2764–2772.Direct Link:
- , . 1999. The role of p53 in tumour suppression: lessons from mouse models, Cell Mol Life Sci 55:48–63.
- , , , . 2002. Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. Carcinogenesis 23:817–822.
- , , , , , , . 1998. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17:1061–1068.
- , , , , , , , , . 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282–288.
- , , , , , . 2000a. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. Embo J 19:4967–4975.
- , , , , . 2000b. Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc Natl Acad Sci USA 97:11936–11941.
- , , , . 2000, Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14:278–288.
- , , , , , , , , , , , , , . 1999. Essential role for oncogenic Ras in tumour maintenance. Nature 400:468–472.
- , , , , , , . 2002. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function, Proc Natl Acad Sci USA 99:2948–2953.
- , , , , , , , . 1993. Gain of function mutations in p53. Nat Genet 4:42–46.
- , , , , , , . 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–221.
- , , , , , , , , . 1995. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 14:16–22.Direct Link:
- , . 1997. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 3:390–395.
- , , , , , . 2001. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20:4041–4049.
- , . 1999. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4:199–207.
- , . 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046–1049.
- , , , , , , , , , , . 2002. mdmx is a negative regulator of p53 activity in vivo. Cancer Res 62:3221–3225.
- , , , , , . 1993. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5:225–229.
- , , , , , , , , . 2000. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287:1824–1827.
- , , , , , , . 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1–7.
- , . 2000. MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 20:1001–1007.
- , , , , , , , . 2000. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat Genet 26:37–43.
- , , , , , , . 2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111–1116.
- , , , . 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206–208.
- , , , , , , , , 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597.
- , . 1996. p53: puzzle and paradigm. Genes Dev 10:1054–1072.
- , , , , , , , . 2000. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am J Pathol 157:2151–2159.
- , , , . 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8:1235–1246.
- , , , , , , . 2000. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97:4174–4179.
- , , , , , , , . 1994. p53 status and the efficacy of cancer therapy in vivo. Science 266:807–810.
- , . 1998. Mouse models dissect the role of p53 in cancer and development. Semin Cancer Biol 8:337–344.
- , , . 1992. myc function and regulation. Annu Rev Biochem 61:809–860.
- , . 2002. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 12:53–59.
- , , , , , , , , . 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22:5527–5538.
- , , . 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203–206.
- , , . 2000. A male germ cell tumor-susceptibility-determining locus, pgct1, identified on murine chromosome 13. Proc Natl Acad Sci USA 97:8421–8426.
- , , , , . 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83.
- , , , , , , . 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29:92–95.
- , , . 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049–1051.
- , , . 1999. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. Embo J 18:1815–1823.
- , , , , . 2000. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14:289–300.
- , , , , , , , , , , . 1996. MDMX: a novel p53-binding protein with some functional properties of MDM2. Embo J 15:5349–5357.
- , , , , , , . 2000. Hdmx stabilizes Mdm2 and p53. J Biol Chem 275:28039–28044.
- , , , , , , . 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703–711.
- , , , , . 1998. A test of the role of alpha5 integrin/fibronectin interactions in tumorigenesis. Cancer Res 58:848–853.
- , , , , , , , . 1999. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. Embo J 18:1805–1814.
- , . 2002. Cancer modeling in the modern era: progress and challenges. Cell 108:135–144.
- , , , , , , . 1998. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. Embo J 17:4657–4667.
- , , , , , . 2002. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol 22:2441–2449.
- , , . 2001. The ons and offs of inducible transgenic technology: a review. Neurobiol Dis 8:923–932.